Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

Journal of Clinical Oncology

Volumn 36, Issue 4, 2018, Pages 383-390

  Larkin, James ^a   Minor, David ^c   D'Angelo, Sandra ^f   Neyns, Bart ^o   Smylie, Michael ^p   Miller, Wilson H ^q   Gutzmer, Ralf ^r   Linette, Gerald ⁱ   Chmielowski, Bartosz ^e   Lao, Christopher D ^j   Lorigan, Paul ^b   Grossmann, Kenneth ^k   Hassel, Jessica C ^s   Sznol, Mario ^l   Daud, Adil ^d   Sosman, Jeffrey ^v   Khushalani, Nikhil ^h   Schadendorf, Dirk ^t   Hoeller, Christoph ^u   Walker, Dana ⁿ   Kong, George ⁿ   Horak, Christine ⁿ   Weber, Jeffrey ^g,m   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e S Monica Univ of California LA   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

ⁱ WASHINGTON UNIVERSITY   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

^k UNIVERSITY OF UTAH   (United States)

^l YALE CANCER CENTER   (United States)

^m NORTHWESTERN UNIVERSITY   (United States)

ⁿ BRISTOL MYERS SQUIBB   (United States)

^o UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^p CROSS CANCER INSTITUTE   (Canada)

^q MCGILL UNIVERSITY   (Canada)

^r HANNOVER MEDICAL SCHOOL   (Germany)

^s Nationales Centrum fur Tumorerkrankungen   (Germany)

^t UNIVERSITY HOSPITAL ESSEN   (Germany)

^u MEDICAL UNIVERSITY OF VIENNA   (Austria)

^v NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; IMMUNOMODULATING AGENT; IPILIMUMAB; LACTATE DEHYDROGENASE; NIVOLUMAB; PACLITAXEL; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; BRAIN METASTASIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAZARD RATIO; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY; IMMUNOPATHOLOGY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADULT; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE EXACERBATION; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; SECONDARY; SKIN TUMOR; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DACARBAZINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NIVOLUMAB; PACLITAXEL; PROGRESSION-FREE SURVIVAL; SKIN NEOPLASMS; TIME FACTORS; YOUNG ADULT;

EID: 85041205158     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.71.8023     Document Type: Conference Paper

References (24)

1. McArthur GA, Ribas A: Targeting oncogenic drivers and the immune system in melanoma. J Clin Oncol 31:499-506, 2013
2. Menzies AM, Long GV: Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. Eur J Cancer 49:3229-3241, 2013
3. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with meta-static melanoma. N Engl J Med 363:711-723, 2010
4. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
5. Callahan MK, Postow MA, Wolchok JD: Immunomodulatory therapy for melanoma: Ipilimumab and beyond. Clin Dermatol 31:191-199, 2013
6. Wood K, Luke JJ: Optimal use of BRAF targeting therapy in the immunotherapy era. Curr Oncol Rep 18:67, 2016
7. Spain L, Julve M, Larkin J: Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations. Expert Opin Pharmacother 17:1031-1038, 2016
8. Ascierto PA, Kirkwood JM, Grob JJ, et al: The role of BRAF V600 mutation in melanoma. J Transl Med 10:85, 2012
9. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
10. Wang C, Thudium KB, Han M, et al: In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in nonhuman primates. Cancer Immunol Res 2:846-856, 2014
11. Robert C, Schachter J, Long GV, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521-2532, 2015
12. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373: 23-34, 2015
13. Hodi FS, Chesney J, Pavlick AC, et al: Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17: 1558-1568, 2016
14. Weber JS, D'Angelo SP, Minor D, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16: 375-384, 2015
15. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
16. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013
17. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
18. EuroQol Group: EuroQol-A new facility for the measurement of health-related quality of life. Health Policy 16:199-208, 1990
19. Ribas A, Puzanov I, Dummer R, et al: Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol 16:908-918, 2015
20. Hamid O, Puzanov I, Dummer R, et al: Final overall survival for KEYNOTE-002: Pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Presented at the ESMO 2016 Congress, Copenhagen, Denmark, October 7-11, 2016
21. Restifo NP, Smyth MJ, Snyder A: Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer 16:121-126, 2016
22. Shi H, Hugo W, Kong X, et al: Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4:80-93, 2014
23. Rizos H, Menzies AM, Pupo GM, et al: BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res 20:1965-1977, 2014
24. Hauschild A, Agarwala SS, Trefzer U, et al: Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27:2823-2830, 2009